Aimed Bio Inc
0009K0
Company Profile
Business description
Aimed Bio Inc is a preclinical-stage biotechnology company specializing in the development of antibody-based therapeutics, especially antibody-drug conjugates (ADC) and bispecific antibodies. It is a next-generation anticancer technology designed to maximize therapeutic efficacy and reduce side effects compared to existing chemotherapeutic agents by selectively delivering anticancer drugs to cancer cells via antibodies. Its product pipelines are AMB302, AMB303, AMB001, and Others.
Contact
67 Jeongui-ro
10th and 11th floors, MK Tower
Songpa-gu
Seoul
KORT: +82 262850743
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
51
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Proposed legislation removes health insurance rebates.
stocks
Investors overlooking ASX share’s potential
International expansion is a distraction from valuable local business.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,750.20 | 68.30 | -0.77% |
| CAC 40 | 7,952.55 | 129.72 | -1.61% |
| DAX 40 | 23,950.57 | 505.69 | -2.07% |
| Dow JONES (US) | 49,526.17 | 537.29 | -1.07% |
| FTSE 100 | 10,195.37 | 177.56 | -1.71% |
| HKSE | 25,775.53 | 187.20 | -0.72% |
| NASDAQ | 26,225.14 | 410.08 | -1.54% |
| Nikkei 225 | 60,545.49 | 863.80 | -1.41% |
| NZX 50 Index | 12,880.92 | 84.09 | -0.65% |
| S&P 500 | 7,408.50 | 92.74 | -1.24% |
| S&P/ASX 200 | 8,519.70 | 58.20 | -0.68% |
| SSE Composite Index | 4,121.62 | 13.77 | -0.33% |